CMC(SH:600327) 智通财经网·2025-11-24 09:51Core Viewpoint - The company intends to transfer 80% of its stake in Jinhua Lianji Hospital and related debts to Lin Tian Biotechnology, aiming to improve the overall asset quality and operational efficiency of its medical services segment [1] Group 1: Transaction Details - Shanghai Junyao Medical Health Technology Co., Ltd. plans to transfer 80% of its stake in Jinhua Lianji Hospital for 1 yuan [1] - The debts owed to Junyao Medical by Jinhua Lianji amount to approximately 89.99 million yuan, which will be transferred for 580,000 yuan [1] Group 2: Financial Impact - The transaction is expected to reduce the net profit attributable to the parent company by 34.25 million yuan in the consolidated financial statements for 2025 [1] - The transaction will also decrease the equity attributable to the parent company by 34.25 million yuan [1] Group 3: Strategic Implications - The completion of this transaction is anticipated to mitigate the impact of ongoing losses from the transferred entity on the company [1] - The transaction aims to optimize the overall asset quality of the company's medical services business segment and enhance its comprehensive operational efficiency [1]